This communication presents four different assay systems for the determination of myeloperoxidase in body fluids. One is based on conventional chemiluminescence, two on luminescence-amplified enzyme measurement using either spiroadamantane-1,2 dioxetanes with alkaline phosphatase or luminol/peroxidase/ 4-iodophenol coupled with a peroxidase label.
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An alkaline phosphatase-labelled enzyme immunoassay using 4-nitrophenyl phosphate as substrate was performed for comparison.
The assays were tested under routine conditions, which included the establishment of a reference range for EDTA plasma from healthy volunteers (7), together with a comparison between myeloperoxidase, lactoferrin and elastase-oci-proteinase inhibitor complexes in cases of bronchial infection.
The luminescence-enhanced enzyme immunoassays and the immunoenzymometric assay with colorimetric measurement were based on microtitre plate technology (14) , whereas the chemiluminescent immunometric assays used polystyrene balls as solid phase (15) .
Materials and Methods

Materials
Myeloperoxidase was obtained as reference material from Behring-Calbiochem. (Marburg a. d. L., FRG) and was declared as 98% pure giving a single band after electrophoresis.
The myeloperoxidase used as standard in the assays was derived from a pathological urine sample containing approximately 125 mg/1 myeloperoxidase. Dilutions were carried out in foetal calf serum (Gibco, Paisley, GB). Other buffer substances were obtained from different sources. Luminometers for reading 75 χ 12 mm tubes/cuvettes were from Lab. Prof. Dr. Berthold (Type LB 952-16 T; 250-sample chain-luminometer), Wildbad, FRG, or from Stratec (Type SL-300; 300-sample rack-luminometer), Birkenfeld, FRG.
The microtitre plate luminometer (Luminoskan) was from ICNFlow Laboratories (Labsystems Oy), Helsinki, SF.
All machines were capable of performing data reduction with integrated or connected microprocessors/desk top computers.
Methods
Immunometric assays were used throughout. Table 1 shows the  flow scheme for the assays based on polystyrene balls, table 2 for assays based on microtitre plates. The basic details of the assays have been published several times for different components elsewhere (7, 12) and need not be further dealt with here.
Tab. 1. Assay flow scheme for polystyrene ball-based immunometric assays for myeloperoxidase using "direct-labelling" of the antibody. The assay buffer and throughout, unless otherwise specified, was: 0.05 mol/1 phosphate, 0.15 mol/1 NaCl, 0.5 ml/1 Triton X-405, pH 7.5. The substrates for the (luminescent-enhanced) enzyme immuno-assays were used as follows: a) AMPPD -0.4 mmol/1 in 0.1 mol/1 diethanolamine buffer b) 4-nitrophenyl phosphate -1 tablet in 15 ml diethanolamine buffer. c) Luminol-peroxidase Signal Reagent Buffer (contents not declared), pH 9.0
All substrate working solutions were prepared directly before use and were discarded afterwards. Only AMPPD was stored as a stock solution in the dark at 4 -7 °C.
Statistics
Non-parametric statistics were used throughout, after the Kolmogorov-Smirnoff lest showed non-normal distributions in several data groups (a > 0.05). Correlations were made using the Spearman rank test, graphical representations using the two regression line technique -y = a + bx and χ = a 4-by. The relevant percentiles and median values were used as locators.
Results and Discussion
Results a) Polystyrene ball-based assays using ABEN as label Figure 1 shows a typical standard curve for assays using a direct label. 
b) Establishment of a reference range for plasma from normal healthy volunteers
EDTA plasma was used throughout. The time between blood sampling and separation of plasma was 2 -30 min (7). Haemolysed samples were discarded, as were plasma samples from volunteers with elevated aminotransferases, γ-glutamyl transferase, C-reactive protein and neopterin. Table 3 shows 10 consecutive assays using the assay described in 
c) Comparison of white blood cell constituents
Elastase-o^-proteinase inhibitor, lactoferrin and myeloperoxidase values in 49 patients with pulmonary disease or infection using the assay in table 1 were compared. The correlation between elastase-oci-proteinase inhibitor and lactoferrin was 0.667, with myeloperoxidase 0.725. The correlation between lactoferrin and myeloperoxidase was 0.521. All correlation coefficients were significant (p < 0.001 -Spearman rank correlation). The distribution of myeloperoxidase concentrations is given in table 3. Table 4 shows the basic data of the assays described in section a) above in the form of compound precision profiles for intra-assay variation, and conventionally with mean values and coefficients of variation for inter-assay comparison. 
d) Inter-and intra-assay variations
e) Micro litre plate-based luminescence enhanced immunoenzymometric assays (LEIA) using an alkaline phosphatase label
The luminescent substrate AMPPD is stable at pH 9.8. The substance is a dioxetane, which is a direct precursor of molecules which luminesce, independent of bio-or chemiluminescence. Through the action of alkaline phosphatase, the AMPPD ~-anion yields a constant light signal (11) . Figure 2 shows the light reaction kinetics in the form of a standard curve read at 1, 5, 10, 60, 90 and 180 minutes after substrate was pipetted into the microtitre plate wells. The light signal could be measured over 60 minutes without appreciable loss of signal or loss in precision or dynamic range of the assay.
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f) Conventional immunoenzymometric assay using alkaline phosphatase 4-nitrophenyl phosphate
As a control system, 4-nitrophenyl phosphate in the colorimetric determination replaced the AMPPD (see (e)). The colour reaction was stopped after 10 minutes with 50 μΐ of 0.25 mol/1 EDTA adjusted to pH 13 with solid NaOH. The colour was read at 405 nm. Colourless microtitre plates replaced the opaque ones used in (e) above.
g) Peroxidase system using luminoljper oxide 4-iodophenol
The combination of peroxidase with luminol and peroxide has been known for over a decade (13) and is used with success commercially. The light signal can be "enhanced" (amplified) by using phenolic derivatives such as 4-iodophenol.
The light signal is also stable as shown in figure 3 . The assay can be measured up to 30 minutes after substrate addition. The reagents used here were exactly as supplied by Amersham International in their Amerlite Signal Reagent kit.
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Myeloperoxidase [ug/l] Figure 4 shows standard curves for the two luminescence-enhanced enzyme immunoassays as well as for the assay with colorimetric detection. All three assays were set up at the same time using identical reagents, with the exception of the streptavidin-enzyme/substrate reagents. The dynamic range of the assays, measured by the ratio of the signal of the 600 μg/l standard to the zero standard (after substraction (see table 2 ). All reactions took place at ambient temperature (18-25°C).
-* -LEIA-POD --+ --LEIA-AP ········· EIA-AP of the reagent blank) was 180:1 for the luminolperoxidase system, 150:1 for AMPPD and 65:1 for the 4-nitrophenyl phosphate system. These data were the optimal values measured 5 minutes after substrate addition for the luminol/peroxide system, after 30 minutes for the AMPPD system and after 10 minutes for the 4-nitrophenyl phosphate system.
i) Precision of microutre plate assays
The precision of microtitre plate assays is similar to that for the polystyrene ball-based assays. This is clearly shown by comparison of the data in tables 4 and 5. oratory internal urinary standard. The correlation data show that an excellent consensus between both standards was achieved. Mass units were used in routine assays as an immunoassay does not necessarily reflect enzymic activity.
Only irradiated microtitre plates were suitable, the capacity of normal plates to adsorb antibody not being sufficient. Normal plates could be made into "high-capacity" plates by pretreatment with poly phenylalanine-lysine/pentan-l,5-dial as described in the literature (15, 16) .
j) Standardisation of the myeoloperoxidase assay
As there are no international reference preparations for myeloperoxidase, comparison was made between the laboratory standard, extracted from urine of a patient with acute renal rejection, and a commercially available myeloperoxidase preparation (Behring-Calbiochem) with declared activity and purity.
The protein content of the commercial preparation was determined using bovine serum albumin as standard and the Biorad protein assay based on Coomassie blue reaction. A value of 120 μg/U was measured. Figure 5 shows serial dilutions of the commercial standard from 8 assays as measured against the lab-
k) Comparison of results from the direct labelled assay using polystyrene balls with those from the AMPPD I alkaline phosphatase microtitre plate assay
One hundred and sixty plasma samples were measured simultaneously in 8 consecutive assays using ABEN or AMPPD as luminogen. Myeloperoxidase concentrations ranged from 72 to 1310 μg/l. The Spearman rank correlation coefficient was 0.984, the slopes of the regression lines y = a + bx and χ = a + by, being 0.972 and 1.018 respectively. This data confirmed that both assays measured the same concentrations within statistically acceptable limits.
I) Final discussion points
We demonstrate not only new assay systems for the non-radioisotopic determination of myeloperoxidase in body fluids, but also support the claims made over a decade ago (17) that if an assay is well designed, the choice of label is often of secondary importance.
The assays based on enhanced luminescence allow one of the basic criticisms and drawbacks of chemiluminescence-based measurements -namely the "one-off measurement -to be overcome.
The use of a luminescent detection system in combination with an enzyme label allows the Beer-Lambert law for colorimetric measurements to be overcome. The low, non-specific signal of AMPPD reduces the lower detection limit, at the same time increasing the measuring range of the assay.
The stability of reagents is excellent, for example the streptavidin-alkaline phosphatase used in this study was kept in solution for over 2 years stored at 4 °C. ABEN-labelled antibodies have shelf lives of over 5 years, when stored under -27 °C.
The use of microtitre plate luminometers, combined with assays which need no reagent injection step in the instrument, make this system attractive and reduces the costs of instrumentation. It also allows those who aready possess such a luminometer, for example, the Amerlite system, to develop and implement their own assays, either using peroxidase or alkaline phosphatase as labels.
